skip to Main Content
Special Pathogens Research Network Ltd. +256700488917 [email protected]
Excellence Beyond Expectation !
Viral, COVID Research

COVID Research a call for action.

COVID research, unfold in case of global, you may wish to know. While we are committed to giving you updates on the COVID epidemic and COVID research, we invite you to join the research on confirming many proposed solutions not just vaccines for preventive profilaxis. We have also published a previously published information from the world Health health organization in case you missed our former publication. What matters to us is the speed at which the facts are circulated while the original authors and publication as adequately cited. Nevertheless, should there be anyone who will insist his or her possessions are original and do not support research with COVID, the person should indicate according to our background.

COVID Research info from MedChemExpress

From MedChemExpress

As COVID 2019 SARS-CoV-2 — The Battle against Coronavirus has just Begun• SARS-CoV-2 showed highly pathogenic, caused severe or even life-threatening diseases, and still transmitted from person-to-person.• The World Health Organization declared a global pandemic as the coronavirus (SARS-CoV-2) rapidly spreads across the world.• Until now, no drugs or biologics have been proven to be effective for the prevention or treatment of COVID-19.SARS-CoV-2 — Promising Antiviral Agents
Favipiravir
(T-705)
(Selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Shows good clinical efficacy in treating COVID-19 but there must be COVID research to support this.
Remdesivir in COVID Research
(GS-5734)
A nucleotide analog inhibitor of RdRp. Against SARS-CoV, MERS-CoV and Ebola virus. Effectively inhibits SARS-CoV-2 in vitro. Enters phase III trial.
Chloroquine
Phosphate
An antimalarial agent. Inhibits autophagy and toll-like receptors (TLRs). Effectively inhibits SARS-CoV-2 in vitro. FDA approved.
Hydroxychloro-
quine sulfate
An antimalarial and anti-inflammatory agent. Inhibits TLR7/9 signaling. Efficiently inhibits SARS-CoV-2 infection in vitro. FDA approved.MedChemExpress 
Anti-COVID-19 Compound Library based on Relevant Proteins: We conduct Virtual Screening of approved compound library and clinical compound library based on
3CLpro (PDB ID: 6LU7), RdRp, Spike Glycoprotein (PDB ID: 6VSB), nsp15 (PDB ID: 6VWW), PLpro and ACE2 Structure.Partial Screening Library Data :SARS-CoV-2 and CompoundsInformation
3CLpro: Saquinavir – An HIV Protease inhibitor. FDA approved. Carfilzomib-An irreversible proteasome inhibitor. FDA approved.
Nelfinavir-An orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) and antiviral agent. FDA approved.
S Protein & ACE2 Bimosiamose A non-oligosaccharide pan-selectin inhibitor and has anti-
inflammatory effects. Phase 2.
RdRp Zanamivir An influenza viral neuraminidase inhibitor. FDA approved.
nsp15 Ribavirin – An antiviral agent against a broad spectrum of viruses including HCV, HIV, and RSV. FDA approved.
PLpro Epetraborole hydrochloride A leucyl-tRNA synthetase (LeuRS) inhibitor. Intended for the infections caused by Gram-negative bacteria. Phase 2.
MCE USA Tel: 609-228-6898E-mail: [email protected]Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAMCE EuropeTel: +4686500910E-mail: [email protected]Address: Bergkällavägen 37C 192 79 Sollentuna SWEDEN
Products are for research use only and are not intended for human use. We do not sell to patients. We respect your privacy and do not share or sell your information to third parties. If you no longer wish to receive these emails you may unsubscribe at any time.

From WHO website

COVID-19 CORONAVIRUS / COVID Research WHO Timeline related to the Wuhan Coronavirus

The coronavirus COVID-19 is affecting 188 countries and territories around the world and 1 international conveyance (the Diamond Princess cruise ship harbored in Yokohama, Japan). The day is reset after midnight GMT+0.

  • Jan. 30
    WHO declares the coronavirus outbreak a Global Public Health Emergency after holding its third Emergency Committee. It recommends that the interim name of the disease-causing the current outbreak should be “2019-nCoV acute respiratory disease”
  • Jan. 29
    WHO states that the mortality rate is estimated at 2.0% but still to early to tell. Praises China for its incredible measures to contain the virus.
  • Jan. 27
    WHO admits an error in its previous risk assessment of the virus and states declares the risk to be “very high in China, high at the regional level and high at the global level.” explaining that it has stated “incorrectly” in its previous reports on January 23, 24, and 25 that the global risk was “moderate”.
  • Jan. 23
    WHO declares the outbreak an “emergency in China”, but stops short of calling it a global health emergency.
  • Jan. 20 (Human to human transmission confirmed)
  • Jan. 15 – Jan 20 (The virus spreads to other countries, including Japan and the United States)
  • Jan. 13 (First case outside of China)
    WHO: “The possibility of cases being identified in other countries was not unexpected, and reinforces why WHO calls for ongoing active monitoring and preparedness in other countries. […] The patient’s full exposure history is under investigation. She reported a history of visiting a local fresh market in Wuhan on a regular basis prior to the onset of illness on January 5, 2020; however, she did not report visiting the Hunan South China Seafood Market from where most of the cases were detected.”
  • Jan. 12 (China shares the genetic sequence of the novel coronavirus for countries to use in developing specific diagnostic kits)
    The WHO says that according to the preliminary epidemiological investigation, most cases worked at, or were handlers and frequent visitors to the seafood market and that “the government reports that there is no clear evidence that the virus passes easily from person to person.”
  • Jan. 9 (First death: a 61-year-old man from Wuhan)
    WHO: “according to Chinese authorities, the virus in question can cause severe illness in some patients and does not transmit readily between people.”
  • January 7 (Novel virus identified and named 2019-nCoV)
    The WHO finds that the new virus is a new strain of coronavirus. The source is still unknown, but most likely comes from animals.
  • December 31, 2019
    The WHO says it had been alerted to a “cluster of cases of pneumonia of unknown cause” in Wuhan, China.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept